文献速递皮肤肿瘤

黑色素瘤患者接受电化学治疗后健康相关生活质量的变化轨迹:来自InspECT登记的真实世界洞察

Health-related quality of life trajectories in melanoma patients after electrochemotherapy: real-world insights from the InspECT register.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-07-23

研究基于InspECT登记的前瞻性数据,评估378例黑色素瘤皮肤转移患者电化学治疗前后健康相关生活质量。完全缓解率47%,3级毒性5%,一年局部无进展生存率78%。生活质量总体保持稳定,完全缓解者尤为稳定;疼痛/不适和活动能力短暂恶化,自我照顾和日常活动持续下降;联合检查点抑制剂与更好生活质量轨迹相关。

要点

  • 电化学治疗后患者生活质量总体与欧洲一般人群相当,完全缓解者生活质量得以保持。
  • 疼痛/不适和活动能力短暂恶化(四个月内恢复),自我照顾和日常活动持续下降。
  • 基线EQ-5D是完全缓解的唯一独立预测因素(RR 14.76,p=0.001)。

核心结论

  • 电化学治疗黑色素瘤患者的生活质量与一般人群相当,完全缓解者生活质量得以保持。
  • 疼痛/不适和活动能力短暂恶化、自我照顾和日常活动持续下降可能需要针对性支持干预。
  • 联合检查点抑制剂与更好的生活质量结局相关。
  • 基线生活质量提供预测信息,有助于识别最可能应答的患者。

研究设计与样本

  • 分析纳入国际电化学治疗实践共享网络(InspECT)登记的前瞻性数据,共378例患者(占黑色素瘤队列的76%)。
  • 患者按标准操作程序接受静脉或瘤内博来霉素(15000 IU/m2;1000 IU mL/cm3),随后给予100微秒、1000 V/cm电脉冲。

主要发现

  • 中位肿瘤大小为2 cm,完全缓解率47%,3级毒性发生率5%,一年局部无进展生存率78%。
  • 基线时年龄配对的生活质量与欧洲一般人群无差异。
  • 电化学治疗后EQ-5D和EQ-VAS评分均保持在最小重要差异边界内,完全缓解者尤为明显。
  • EQ-5D子项分析显示疼痛/不适和活动能力统计学显著恶化(四个月内恢复),自我照顾和日常活动在整个随访期间持续下降。
  • 基线EQ-5D是完全缓解的唯一独立预测因素(RR 14.76,p=0.001)。

关键数值与推荐

  • 疗效评估采用RECIST v3.0,局部无进展生存期,毒性采用CTCAE v5.0。
  • 生活质量评估采用EuroQol(EQ-5D-3L),包括5项效用评分(EQ-5D)和自报健康状态视觉模拟量表(EQ-VAS),在基线、1、2、4和10个月评估。
  • 完全缓解率47%,3级毒性5%,一年局部无进展生存率78%(378例患者)。
  • 基线EQ-5D预测完全缓解的RR为14.76(p=0.001)。

临床怎么用

  • 电化学治疗可用于控制黑色素瘤皮肤转移,生活质量总体保持稳定。
  • 对疼痛/不适、活动能力、自我照顾和日常活动领域的恶化可考虑针对性支持干预。
  • 联合检查点抑制剂可能与更好的生活质量结局相关。
  • 基线生活质量评估有助于识别最可能从电化学治疗中应答的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Electrochemotherapy (ECT) effectively controls skin metastases from cutaneous melanoma. OBJECTIVES: This study aimed to evaluate health-related quality of life (HRQoL) in melanoma patients pre-/post-ECT and its effect on treatment outcome. METHODS: The analysis included prospective data from the International Network for Sharing Practices of ECT register. Following the Standard Operating Procedures, patients received intravenous or intratumoural bleomycin (15,000 IU/m2 ; 1000 IU mL/cm3 ) followed by 100-microsecond, 1000-V/cm electric pulses. Endpoints included response (RECIST v3.0), local progression-free survival (LPFS), toxicity (CTCAE v5.0), and patient-reported HRQoL at baseline, one, two, four and ten months (EuroQol [EQ-5D-3L], including 5-item utility score [EQ-5D] and visual analogue scale for self-reported health state [EQ-VAS]). Comparisons within/between subgroups were made for statistical and minimal important differences (MID). HRQoL scores and clinical covariates were analysed to identify predictors of response in multivariate analysis. RESULTS: Median tumour size was 2 cm. Complete response rate, G3 toxicity and one-year LPFS in 378 patients (76% of the melanoma cohort) were 47%, 5%, and 78%. At baseline, age-paired HRQoL did not differ from the general European population. Following ECT, both EQ-5D and EQ-VAS scores remained within MID boundaries, particularly among complete responders. A subanalysis of the EQ-5D items revealed a statistically significant deterioration in pain/discomfort and mobility (restored within four months), and self-care and usual activities (throughout the follow-up) domains. Concomitant checkpoint inhibition correlated with better EQ-5D and EQ-VAS trajectories. Baseline EQ-5D was the exclusive independent predictor for complete response (RR 14.76, p=0.001). CONCLUSIONS: HRQoL of ECT melanoma patients parallels the general population and is preserved in complete responders. Transient deterioration in pain/discomfort and mobility and persistent decline in self-care and usual activities may warrant targeted support interventions. Combination with checkpoint inhibitors is associated with better QoL outcomes. Baseline HRQoL provides predictive information which can help identify patients most likely to respond.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Campana LG, Quaglino P, de Terlizzi F, et al. Health-related quality of life trajectories in melanoma patients after electrochemotherapy: real-world insights from the InspECT register. J Eur Acad Dermatol Venereol. 2022. PMID: 35870122. doi:10.1111/jdv.18456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。